[go: up one dir, main page]

PE20211809A1 - Derivados de espirocromano - Google Patents

Derivados de espirocromano

Info

Publication number
PE20211809A1
PE20211809A1 PE2021000053A PE2021000053A PE20211809A1 PE 20211809 A1 PE20211809 A1 PE 20211809A1 PE 2021000053 A PE2021000053 A PE 2021000053A PE 2021000053 A PE2021000053 A PE 2021000053A PE 20211809 A1 PE20211809 A1 PE 20211809A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
dihydrospiro
benzopyran
indol
Prior art date
Application number
PE2021000053A
Other languages
English (en)
Inventor
Janos Eles
Molnar Katalin Dudasne
Istvan Ledneczki
Pal Tapolcsanyi
Anita Horvath
Zsolt Nemethy
Gyorgy Istvan Levay
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of PE20211809A1 publication Critical patent/PE20211809A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Esta referido a un compuesto de Formula I, en donde: A es un heterociclo de cinco o seis miembros; B es un carbociclo o heterociclo de seis miembros; X, Y, Z son C o N; R1 es H, alquilo, halogeno, haloalquilo; R2 es H, O; R3 es H, alquilo, halogeno, haloalquilo, alcoxi; R4, R5 son H, alquilo; n, m son 1, 2; W es O, S. Entre los compuestos preferidos tenemos los siguientes: 6'-Fluoro-N-[(2-metil-1H-indol-5-il)metil]-4'-oxo-3',4'- dihidroespiro[azetidin-3,2'-[1]benzopiran]-1-carboxamida; 7'-fluoro-N-[(1-metil-1H-indol-5-il)metil]-4'-oxo-3',4'-dihidroespiro[azetidin3,2'-[1]benzopiran]-1-carboxamida; entre otros. Estos compuestos son moduladores de la actividad del receptor nicotinico de acetilcolina a7 y se emplean en el tratamiento de esquizofrenia, deterioro cognitivo como resultado de un accidente cerebrovascular, enfermedad de Alzheimer, enfermedad de Huntington, entre otras.
PE2021000053A 2018-07-13 2019-07-12 Derivados de espirocromano PE20211809A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1800248A HU231333B1 (hu) 2018-07-13 2018-07-13 Spirokromán származékok
PCT/IB2019/055948 WO2020012422A1 (en) 2018-07-13 2019-07-12 Spirochromane derivatives

Publications (1)

Publication Number Publication Date
PE20211809A1 true PE20211809A1 (es) 2021-09-14

Family

ID=89992725

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000053A PE20211809A1 (es) 2018-07-13 2019-07-12 Derivados de espirocromano

Country Status (24)

Country Link
US (1) US20210330650A1 (es)
EP (1) EP3820869B1 (es)
JP (1) JP7487167B2 (es)
KR (1) KR20210033002A (es)
CN (1) CN112823157B (es)
AR (1) AR115782A1 (es)
AU (1) AU2019300514B2 (es)
BR (1) BR112020026996A2 (es)
CA (1) CA3104258A1 (es)
CL (1) CL2021000080A1 (es)
CO (1) CO2021001216A2 (es)
CU (1) CU24680B1 (es)
EA (1) EA202190245A1 (es)
ES (1) ES2964617T3 (es)
GE (1) GEP20237534B (es)
HU (2) HU231333B1 (es)
IL (1) IL279938B2 (es)
MX (1) MX2021000460A (es)
MY (1) MY206779A (es)
PE (1) PE20211809A1 (es)
PH (1) PH12020552183A1 (es)
SG (1) SG11202012594RA (es)
TW (1) TWI821321B (es)
WO (1) WO2020012422A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
JP2023520647A (ja) 2020-03-26 2023-05-18 リヒター ゲデオン ニュイルヴァーノシャン ミューコェデー レースヴェーニュタールシャシャーグ ＧＡＢＡ Ａアルファ５受容体調節剤としてのナフチリジンおよびピリド［３，４－ｃ］ピリダジン誘導体
CN115403579A (zh) * 2021-05-27 2022-11-29 上海拓界生物医药科技有限公司 一种新的螺环衍生物及其用途
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1782811A4 (en) 2004-08-09 2010-09-01 Eisai R&D Man Co Ltd INNOVATIVE ANTIPALUDITIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
ES2632940T3 (es) 2005-09-13 2017-09-18 Janssen Pharmaceutica Nv Derivados de tiazol sustituidos con 2-anilin-4-arilo
CN101490056A (zh) * 2006-05-17 2009-07-22 阿斯利康(瑞典)有限公司 烟碱乙酰胆碱受体的配体101
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
EP2134713A2 (en) 2006-12-20 2009-12-23 Schering Corporation Novel jnk inhibitors
EP2207540B1 (en) 2007-10-04 2014-02-26 F. Hoffmann-La Roche AG Cyclopropyl aryl amide derivatives and uses thereof
ES2443290T3 (es) 2007-10-04 2014-02-18 F. Hoffmann-La Roche Ag Derivados arilamida sustituidos con tetrazol y usos de los mismos
BRPI0907492A2 (pt) 2008-02-07 2017-06-13 Abbott Lab derivados amida como moduladores alostéricos positivos e métodos de sua utilização
MX2010010127A (es) 2008-03-19 2010-10-25 Janssen Pharmaceutica Nv 1,2,4-triazoles trisustituidos como moduladores de receptores de acetilcolina nicotinicos.
EP2110377A1 (en) * 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
BRPI0910585A2 (pt) 2008-04-17 2015-09-22 Glaxo Group Ltd indóis como moduladores de receptor de aceticolina nicotínica do subtipo alfa-7
CN102015655A (zh) 2008-05-09 2011-04-13 詹森药业有限公司 作为乙酰胆碱受体调节剂的三取代吡唑类
JP2011524864A (ja) 2008-05-30 2011-09-08 メルク・シャープ・エンド・ドーム・コーポレイション 新規な置換されたアザベンゾオキサゾール
EP2519524A4 (en) 2009-12-31 2013-07-03 Hutchison Medipharma Ltd CERTAIN TRIAZOLOPYRIDINE AND TRIAZOLOPYRZINE, COMPOSITIONS AND METHOD OF USE
WO2012042915A1 (en) 2010-10-01 2012-04-05 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists
EP2970180A1 (en) * 2013-03-13 2016-01-20 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
TN2018000322A1 (en) * 2016-03-22 2020-01-16 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
US10870630B2 (en) 2016-11-01 2020-12-22 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
CA3046805A1 (en) * 2016-12-14 2018-06-21 89Bio Ltd. Spiropiperidine derivatives

Also Published As

Publication number Publication date
EP3820869B1 (en) 2023-08-30
MX2021000460A (es) 2021-06-23
AU2019300514A1 (en) 2021-02-11
HUP1800248A2 (en) 2020-01-28
CL2021000080A1 (es) 2021-10-29
JP7487167B2 (ja) 2024-05-20
CN112823157A (zh) 2021-05-18
CO2021001216A2 (es) 2021-02-26
ES2964617T3 (es) 2024-04-08
CN112823157B (zh) 2024-08-09
US20210330650A1 (en) 2021-10-28
PH12020552183A1 (en) 2021-06-21
CA3104258A1 (en) 2020-01-16
BR112020026996A2 (pt) 2021-04-06
HU231333B1 (hu) 2023-01-28
AR115782A1 (es) 2021-02-24
SG11202012594RA (en) 2021-02-25
MY206779A (en) 2025-01-07
IL279938B2 (en) 2025-01-01
AU2019300514B2 (en) 2023-02-02
JP2021531260A (ja) 2021-11-18
GEP20237534B (en) 2023-09-11
WO2020012422A1 (en) 2020-01-16
TWI821321B (zh) 2023-11-11
CU20200108A7 (es) 2021-07-02
TW202035399A (zh) 2020-10-01
EA202190245A1 (ru) 2021-04-20
CU24680B1 (es) 2023-10-06
KR20210033002A (ko) 2021-03-25
IL279938B1 (en) 2024-09-01
EP3820869A1 (en) 2021-05-19
HUE064417T2 (hu) 2024-03-28
IL279938A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
PE20211809A1 (es) Derivados de espirocromano
PE20211784A1 (es) Tolillo sustituido como fungicidas
PE20130155A1 (es) Derivados de ariletinilo
PE20211911A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
PE20210040A1 (es) Moduladores de la via de estres integrada
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
AR044037A1 (es) Compuestos de pirazol e imidazol biciclicos como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
PE20191156A1 (es) Nuevos derivados de isoxazolil eter como pam de gabaa alfa5
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20060336A1 (es) Compuestos derivados de 1-amino-ftalazina como moduladores de mch1
AR043014A1 (es) Amino-1,3,5-triazinas n-sustituidas con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas, y su uso como herbicidas y reguladores del crecimiento de las plantas
AR066781A1 (es) Compuestos de imidazopirimidina inhibidores de cinasa
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
PE20160691A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
PE20080842A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
AR054799A1 (es) Derivados de oxindol
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
PE20070790A1 (es) Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4